CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...
Around the turn of the century, microbiologists at Danisco USA Inc. had a problem: The bacteria they used to make yogurt and cheese were getting infected with viruses. Investigating more deeply, the ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
A powerful form of DNA-editing machinery discovered in bacteria might allow us to make much bigger changes to genomes than is currently possible with CRISPR-based techniques. However, it isn’t yet ...
StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report released on Thursday. Other analysts have also issued reports about the stock.
Hello, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst at H.C. Wainwright. Today, I have the pleasure of welcoming CRISPR Therapeutics. And from the company, Raj Prasad, CFO, is ...
Key opportunities in the market include leveraging CRISPR's precision for improved crop traits, meeting food security demands amid climate change, and sustainable agriculture trendsDublin, Dec. 09, ...
At STAT Summit 2025, Joe Kennedy III, AMA President, and Leaders debate CRISPR, pharma, public health, policy & more. Kyle, Nicole, and KJ Muldoon, a family on the receiving end of a gene-editing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback